Neovacs S.A SMA 200
Was ist das SMA 200 von Neovacs S.A?
SMA 200 von Neovacs S.A. ist €0 +100.00%
Was ist die Definition von SMA 200?
SMA 200 ist ein durchschnittlicher Aktienkurs der letzten 200 Tage, berechnet als ungewichteter Mittelwert der letzten 200 Schlusskurse.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 von Unternehmen in Health Care Sektor auf EURONEXT im Vergleich zu Neovacs S.A
Was macht Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Unternehmen mit sma 200 ähnlich Neovacs S.A
- Neovacs S.A hat SMA 200 von €0 +100.00%
- EVmo Inc hat SMA 200 von $0 +96.08%
- Predictive Technology hat SMA 200 von $0 +26.47%
- Kaleido Biosciences Inc hat SMA 200 von $0 +25.93%
- Identillect Technologies hat SMA 200 von CAD$0 +98.52%
- Atlas hat SMA 200 von $0 +79.84%
- Cycliq hat SMA 200 von AUD$0 +98.35%